TriangleNCT00356031 · OUTCOME
Average Change in Blood Flow, Blood Volume,and Permeability Surface Area
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Percent Reduction
- Interval / dispersion
- Full Range
- Time frame
- 3 years
What was measured
The percentage reduction in blood flow, blood volume,and permeability surface area of the tumor following combination therapy as determined by perfusion CT (computerized tomography) scan. The percent change represents the combined average percent change for flow, volume, and permeability together.
Groups in this outcome
Bevacizumab, Radiation, and Surgery
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
| Group | Source count |
|---|---|
| Bevacizumab, Radiation, and Surgery | 20 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bevacizumab, Radiation, and Surgery | 67 | Not reported | 62 | 72 | Not reported |
Source statistical analyses
- group Ids
- OG000
- non Inferiority Type
- OTHER
- p Value
- <.05
- statistical Method
- t-test, 1 sided
Complete source fields
- analyses
- group Ids
- OG000
- non Inferiority Type
- OTHER
- p Value
- <.05
- statistical Method
- t-test, 1 sided
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 62
- upper Limit
- 72
- value
- 67
- denoms
- counts
- group Id
- OG000
- value
- 20
- units
- Participants
- description
- The percentage reduction in blood flow, blood volume,and permeability surface area of the tumor following combination therapy as determined by perfusion CT (computerized tomography) scan. The percent change represents the combined average percent change for flow, volume, and permeability together.
- dispersion Type
- Full Range
- groups
- description
- Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
- id
- OG000
- title
- Bevacizumab, Radiation, and Surgery
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- 3 years
- title
- Average Change in Blood Flow, Blood Volume,and Permeability Surface Area
- type
- SECONDARY
- unit Of Measure
- Percent Reduction
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice